Solventum Corporation $SOLV Stake Decreased by Clifford Capital Partners LLC

Clifford Capital Partners LLC lowered its position in Solventum Corporation (NYSE:SOLV) by 12.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 308,680 shares of the company’s stock after selling 43,541 shares during the quarter. Solventum comprises about 4.2% of Clifford Capital Partners LLC’s portfolio, making the stock its 2nd largest position. Clifford Capital Partners LLC owned 0.18% of Solventum worth $24,460,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Hilltop National Bank raised its stake in shares of Solventum by 71.3% in the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after acquiring an additional 129 shares during the period. Measured Wealth Private Client Group LLC purchased a new stake in shares of Solventum in the third quarter valued at $25,000. JNBA Financial Advisors raised its stake in shares of Solventum by 205.4% in the fourth quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after acquiring an additional 228 shares during the period. CYBER HORNET ETFs LLC purchased a new stake in shares of Solventum in the second quarter valued at $28,000. Finally, City State Bank raised its stake in shares of Solventum by 166.7% in the fourth quarter. City State Bank now owns 384 shares of the company’s stock valued at $30,000 after acquiring an additional 240 shares during the period.

Solventum Trading Down 2.7%

SOLV stock opened at $74.48 on Thursday. The company has a market capitalization of $12.90 billion, a PE ratio of 9.13, a P/E/G ratio of 1.18 and a beta of 0.69. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $88.20. The firm’s 50-day moving average is $73.25 and its 200 day moving average is $75.00. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.07 and a quick ratio of 0.75.

Solventum (NYSE:SOLV) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same period in the prior year, the business earned $1.34 EPS. The firm’s quarterly revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Analysts Set New Price Targets

SOLV has been the topic of several recent analyst reports. UBS Group downgraded shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 target price on the stock. in a research note on Thursday, May 14th. Piper Sandler reduced their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. BTIG Research reaffirmed a “buy” rating and issued a $89.00 price target on shares of Solventum in a research note on Wednesday, May 6th. Rothschild & Co Redburn initiated coverage on shares of Solventum in a research note on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target on the stock. Finally, Wedbush initiated coverage on shares of Solventum in a research note on Friday, May 15th. They issued an “outperform” rating and a $94.00 price target on the stock. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $84.25.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.